Pharmacogenetic approaches to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study

Pharmacogenomics Journal

Volumn 2, Issue 5, 2002, Pages 309-317

  Arnett, D K ^a   Boerwinkle, E ^b   Davis, B R ^b   Eckfeldt, J ^c   Ford, C E ^b   Black, H ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amlodipine; Chlorthalldone; Doxazosin; Hypertension; Pharmacogenetics:Genetic polymorphism

Indexed keywords

ADDUCIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPOPROTEIN LIPASE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL STUDY; CORONARY RISK; ETHNIC GROUP; FEMALE; FOLLOW UP; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHARMACOGENETICS; PRIORITY JOURNAL; SEX RATIO; STROKE; SYSTOLIC HYPERTENSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

HUMANS; HYPERTENSION; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036448441     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500113     Document Type: Article

References (35)

1. Ferrari P, Bianchi G. Genetic mapping and tailored antihypertensive therapy. Cardiovasc Drugs Ther 2000; 14: 387-395.
2. O'Byrne S, Caulfield M. Genetics of hypertension. Therapeutic implications. Drugs 1998; 56: 203-214.
3. Pratt RE, Dzau VJ. Genomics and hypertension: concepts, potentials, and opportunities. Hypertension 1999; 33: 238-247.
4. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M et al. Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-1357.
5. ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283: 1967-1975.
6. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Amer J Hypertens 1996; 9: 342-360.
7. Takayanagi R, Ohnaka K, Sakai Y, Ikuyama S, Nawata H. Molecular cloning and characterization of the promoter for human type-1 angiotensin II receptor gene. Biochem Biophys Res Commun 1994; 200: 1264-1270.
8. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24: 63-69.
9. Wu D-A, Bu X, Warden CH, Shen DDC, Jeng C-Y, Sheu WHH et al. Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. J Clin Invest. 1996; 97: 2111-2118.
10. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson GS. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Antherosclerosis 2001 Dec; 159(2): 367-73.
11. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334-339.
12. Lentes K, Berrettini W, Hoeche M, Chung F, Gershon E. A biallelic DNA polymorphism of the human -adrenergic receptor detected by Ban 1-Adrbr-2. Nucleic Acids Res 1988; 16: 2359.
13. Anonymous. The American Society of Human Genetics ASHG Report-Statement on informed consent for genetic research. Am J Hum Genet 1996; 59: 471-474.
14. Peterson B, George SL. Sample size requirement and length of study for testing interaction in a 2 × 4 factorial design when time-to-failure is the outcome. Cont Clin Trials 1993; 14: 511-522.
15. Proschan MA, Waclawiw MA. Practical guidelines for multiplicity adjustment in clinical trials. Cont Clin Trials 2000; 21: 527-539.
16. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC Jr, Ciocon JO et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001; 24: 654-658.
17. Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37: 19-27.
18. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-180.
19. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103: 1644-1648.
20. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-1633.
21. Atwood LD, Kammerer CM, Samollow PB, Hixson JE, Shade RE, MacCluer JW. Linkage of essential hypertension to the angiotensinogen locus in Mexican-Americans. Hypertension 1997; 30: 326-330.
22. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
23. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-712.
24. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M et al. A nucleotide substitution in the promotor of human angiotensinogen is associated with essential hypertension and affects basal transcription in vivo. J Clin Invest 1997; 99: 1786-1797.
25. Hall JE. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994; 23: 381-394.
26. Castellano M, Barlassina C, Muiesan L, Beschi M, Cinelli A, Rossi F et al. α-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997; 15: 1707-1710.
27. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M et al. Association of the α-adducin locus with essential hypertension. Hypertension 1995; 25: 320-326.
28. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokoyama K, Yamauchi A et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995; 6: 1676-1678.
29. Sasaki M, Oki T, Iuchi A, Tabata T, Yamada H, Manabe K et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 1996; 14: 1403-1408.
30. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 4: 259-262.
31. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest. 1995; 96: 2100-2102.
32. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardio Pharmacol 1998; 32: 988-994.
33. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106: 544-549.
34. Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889-897.
35. Myerson SG, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries SE et al. Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with Losartan. Circulation 2001; 103: 226-230.